Advertisement

Topics

Catalyst Biosciences, Inc. Company Profile

10:58 EST 21st November 2017 | BioPortfolio

Catalyst Biosciences is developing the next generation of biopharmaceuticals by harnessing the catalytic power of engineered proteases that target proteins underlying diseases. Catalyst's discovery platform rapidly creates and optimizes tailor-made protease drug candidates that cleave a wide variety of disease targets, either by improving existing protease drugs or by creating new protease drugs, known as Alterase(TM) therapeutics. Catalyst is focusing its product development efforts on drug candidates for hemophilia, non-hemophilic bleeding, and complement-driven diseases, including the prevention of delayed graft function and inflammation. Catalyst has ongoing research, development, and license agreements with Wyeth Pharmaceuticals, a wholly-owned subsidiary of Pfizer Inc. and MedImmune, LLC, the global biologics unit of AstraZeneca plc. Together, these two partnering agreements total up to nearly $700 million in upfront payments, R&D support, and milestone payments, plus royalties on potential future sales. Catalyst is privately held with backing by leading venture firms, including Burrill & Company, Essex Woodlands Health Ventures, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures, RCT BioVentures, and Sofinnova Ventures. For more information, please visit www.catbio.com.


News Articles [848 Associated News Articles listed on BioPortfolio]

Reviewing Catalyst Biosciences

Catalyst Biosciences and Fortress Biotech are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valu...

FDA Grants ODD to Catalyst Biosciences' Hemophilia B Treatment

NewsCatalyst Biosciences granted FDA orphan drug designation for subcutaneous recombinant human Factor IX variant for treatment of hemophilia B.

Catalyst Biosciences and Mosaic Biosciences Enter into Strategic Collaboration to Develop Intravitreal Anti-Complement Factor 3 (C3) Products for the Treatment of Dry AMD and Other Retinal Diseases

Collaboration aims to develop best-in-class anti-C3 intravitreal products with quarterly dosing frequency and better potency C3 is a clinically validated target in dry age-related macular degener...

FDA grants orphan drug status to Catalyst's hemophilia B factor IX variant

Catalyst Biosciences' subcutaneous next-generation recombinant human factor IX variant CB 2679d/ISU304 was designated an orph -More- 

Catalyst Biosciences Announces Positive Factor IX Clinical Data

-- CB 2679d/ISU304 is approximately 22 times more potent than current hemophilia B therapy -- SOUTH SAN FRANCISCO, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq:...

Catalyst Biosciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq:CBIO) today announced that Nassim Usman, Ph.D., President and Chief Executive Officer, will pres...

Catalyst Biosciences Announces Issuance of Asia Patents Covering Factor IX Hemophilia Program

-- CB 2679d/ISU304 has patent coverage in all key commercial territories -- SOUTH SAN FRANCISCO, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), today anno...

Catalyst Biosciences Reports Third Quarter 2017 Operating & Financial Results and Provides Corporate Update

-- Phase 1/2 trial of Factor IX CB 2679d is advancing with interim results expected by year-end -- -- Phase 2 trial of Factor FVIIa marzeptacog alfa (activated) on track for initiation by year-e...

Drugs and Medications [13 Associated Drugs and Medications listed on BioPortfolio]

Naturally nova scotia hand sanitizer [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Natelle one [Azur Pharma, Inc.]

Natelle OneRx Prenatal Vitamin & Plant-Based DHA Now with 28 mg Iron

Natelle one [Azur Pharma, Inc.]

Natelle®OneRx Prenatal Vitamin & Plant-Based DHA

PubMed Articles [563 Associated PubMed Articles listed on BioPortfolio]

A solid iridium catalyst for diastereoselective hydrogenation.

An Ir(NHC) supported catalyst is used in the selective hydrogenation of terpinen-4-ol to cis p-menthan-4-ol. Its activity, selectivity and stability are compared to those of a homogeneous homologue [I...

Switch in Catalyst State: Single Bifunctional Bi-State Catalyst for Two Different Reactions.

Disclosed here is a molecular switch which responds to acid-base stimuli and serves as a bi-state catalyst for two different reactions. The two states of the switch serve as a highly active and poorly...

Overcoming the instability of nanoparticle based catalyst films in alkaline electrolysers by self-assembling and self-healing films.

Engineering stable electrodes using highly active catalyst nanopowders for electrochemical water splitting remains a notorious challenge. We report an innovative and general approach for attaining hig...

Microstructural observation of fuel cell catalyst inks by Cryo-SEM and Cryo-TEM.

In order to improve the electricity generation performance of fuel cell electric vehicles, it is necessary to optimize the microstructure of the catalyst layer of a polymer electrolyte fuel cell. The ...

The Experimental Measurement of Local and Bulk Oxygen Transport Resistances in the Catalyst Layer of Proton Exchange Membrane Fuel Cells.

Remarkable progress has been made in reducing the cathodic Pt loading of PEMFCs, however, a huge performance loss appears at high current densities, indicating the existence of a large oxygen transpor...

Clinical Trials [7 Associated Clinical Trials listed on BioPortfolio]

HepaStem Long-Term Safety Registry

All patients having received at least one infusion of the Investigational Medicinal Product (IMP) HepaStem HHALPC during a previous interventional clinical study conducted by Promethera Bi...

A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer

Chemotherapy regimens for pancreatic cancer can now stabilize a patient's cancer and/or place some patients in remission or partial remission. The challenge now is to find options for main...

Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy

The purpose of this research is to determine if a subject's own bone marrow tissue can help regenerate bone in the area of his/her jaw where a tooth has been removed using Tissue Repair Ce...

Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data

We seek to improve the predictive accuracy of the nomogram to predict survival for patients with castrate mets disease through the addition of pathological data, the results of automated m...

Validation of Decipher Test in African American Men With Prostate Cancer - VANDAAM

The primary purpose of this study is to determine whether a tumor test recently developed by GenomeDx Biosciences known as Decipher® can predict aggressive prostate cancer with the same a...

Companies [442 Associated Companies listed on BioPortfolio]

Targacept, Inc. and Catalyst Biosciences, Inc.

Catalyst Biosciences, Inc.

Catalyst Biosciences is developing the next generation of biopharmaceuticals by harnessing the catalytic power of engineered proteases that target proteins underlying diseases. Catalyst's discovery p...

Catalyst Health and Technology Partners

Catalyst Health and Technology Partners (“Catalyst”), is a venture capital firm dedicated to helping promising early-stage health care, life science, and technology ventures grow.Catalyst is focus...

General Catalyst Partners

General Catalyst Partners is a growth equity and venture capital firm that invests in exceptional entrepreneurs who are building the technology-based companies that will lead inno...

Catalyst Advisors

Catalyst Advisors is a premier executive search firm devoted to finding exceptional boardroom and executive leaders for innovative healthcare and bioscience companies, including t...

More Information about "Catalyst Biosciences, Inc." on BioPortfolio

We have published hundreds of Catalyst Biosciences, Inc. news stories on BioPortfolio along with dozens of Catalyst Biosciences, Inc. Clinical Trials and PubMed Articles about Catalyst Biosciences, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Catalyst Biosciences, Inc. Companies in our database. You can also find out about relevant Catalyst Biosciences, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...


Corporate Database Quicklinks



Searches Linking to this Company Record